Abstract

Multiple sclerosis is a chronic, inflammatory, demyelinating disease which affects the central nervous system and is linked to autoimmune disorders. Although the precise causes of multiple sclerosis remain unknown, some evidence points towards hypovitaminosis D. Apart from the maintenance of calcium and phosphorus homeostasis, vitamin D also plays a major role in other aspects of human health. It is caused by the vitamin D receptor, which is present in many human organs and tissues. Vitamin D is an immunomodulating factor and accordingly has a potential to be effective in both preventing and treating autoimmune diseases, including multiple sclerosis. The aim of this review was to present up-to-date knowledge about vitamin D, especially its impact on risk of multiple sclerosis onset, relapses, and potential to modify the immune response. A further objective was to describe the role of vitamin D supplementation and its provision in the everyday diet for both prevention and treatment of multiple sclerosis.

References

• 1. Adorini L., Penna G.: Control of autoimmune diseases by the vitaminD endocrine system. Nat. Clin. Pract. Rheumatol., 2008; 4: 404-412
  Google Scholar
• 2. Adzemovic M.Z., Zeitelhofer M., Hochmeister S., Gustafsson S.A.,Jagodic M.: Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammationdepends on developmental stage. Exp. Neurol., 2013;249: 39-48
  Google Scholar
• 3. Alonso A., Hernán M.A.: Temporal trends in the incidence of multiplesclerosis: a systematic review. Neurology, 2008; 71: 129-135
  Google Scholar
• 4. Barnett M.H., Williams D.B., Day S., Macaskill P., McLeod J.G.: Progressiveincrease in incidence and prevalence of multiple sclerosis inNewcastle, Australia: a 35-year study. J. Neurol. Sci., 2003; 213: 1-6
  Google Scholar
• 5. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., PenningtonC.J., Bourgoin P., Edwards D.R., Yong V.W.: Analyses of all matrixmetalloproteinase members in leukocytes emphasize monocytesas major inflammatory mediators in multiple sclerosis. Brain, 2003;126: 2738-2749
  Google Scholar
• 6. Becklund B.R., Hansen D.W.Jr., Deluca H.F.: Enhancement of 1,25-dihydroxyvitaminD3-mediated suppression of experimental autoimmuneencephalomyelitis by calcitonin. Proc. Natl. Acad. Sci. USA, 2009;106: 5276-5281
  Google Scholar
• 7. Bluestone J.A., Tang Q.: How do CD4+CD25+ regulatory T cells controlautoimmunity? Curr. Opin. Immunol., 2005; 17: 638-642
  Google Scholar
• 8. Brum D.G., Comini-Frota E.R., Vasconcelos C.C., Dias-Tosta E.: Supplementationand therapeutic use of vitamin D in patients with multiplesclerosis: consensus of the Scientific Department of Neuroimmunologyof the Brazilian Academy of Neurology. Arq. Neuropsiquiatr.,2014; 72: 152-156
  Google Scholar
• 9. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R.,Gagne D., D’Souza C., Ursell M., O’Connor P.: A phase I/II dose-escalationtrial of vitamin D3 and calcium in multiple sclerosis. Neurology,2010; 74: 1852-1859
  Google Scholar
• 10. Cantorna M.T., Mahon B.D.: Mounting evidence for vitamin D as anenvironmental factor affecting autoimmune disease prevalence. Exp.Biol. Med., 2004; 229: 1136-1142
  Google Scholar
• 11. Correale J., Ysrraelit M.C., Gaitan M.I.: Immunomodulatory effectsof vitamin D in multiple sclerosis. Brain, 2009; 132: 1146-1160
  Google Scholar
• 12. Correale J., Ysrraelit M.C., Gaitán M.I.: Gender differences in 1,25dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosispatients and healthy subjects. J. Immunol., 2010, 185: 4948-4958
  Google Scholar
• 13. Debouverie M., Pittion-Vouyovitch S., Louis S., Roederer T., GuilleminF.: Increasing incidence of multiple sclerosis among women inLorraine, Eastern France. Mult. Scler. 2007; 13: 962-967
  Google Scholar
• 14. Ebers G.C.: Environmental factors and multiple sclerosis. LancetNeurol., 2008; 7: 268-277
  Google Scholar
• 15. Fontenot J.D., Gavin M.A., Rudensky A.Y.: Foxp3 programs the developmentand function of CD4+CD25+ regulatory T cells. Nat. Immunol.,2003; 4: 330-336
  Google Scholar
• 16. Granieri E., Casetta I., Tola M.R., Ferrante P.: Multiple sclerosis: infectioushypothesis. Neurol. Sci., 2001; 22: 179-185
  Google Scholar
• 17. Granieri E., Economou N.T., De Gennaro R., Tola M.R., Caniatti L.,Govoni V., Fainardi E., Casetta I.: Multiple sclerosis in the province ofFerrara: evidence for an increasing trend. J. Neurol., 2007; 254: 1642-1648
  Google Scholar
• 18. Grant W.B.: Latitude and multiple sclerosis prevalence: vitamin D reducesrisk of Epstein-Barr virus infection. Mult. Scler., 2010; 16: 373-375
  Google Scholar
• 19. Hatamian H., Bidabadi E., Seyed Saadat S.M., Saadat N.S., KazemnezhadE., Ramezani H., Bakhshayesh B.: Is serum vitamin D levels associatedwith disability in patients with newly diagnosed multiple sclerosis?Iran J. Neurol., 2013; 12: 41-46
  Google Scholar
• 20. Holick M.F.: Sunlight and vitamin D for bone health and preventionof autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin.Nutr., 2004; 80 (Suppl. 6): 1678S-1688S
  Google Scholar
• 21. Holick M.F.: Vitamin D deficiency. N. Engl. J. Med., 2007; 357: 266-281
  Google Scholar
• 22. Hori S., Nomura T., Sakaguchi S.: Control of regulatory T cell developmentby the transcription factor Foxp3. Science, 2003; 299: 1057-1061
  Google Scholar
• 23. Joshi S., Pantalena L.C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-KochanC., Ichiyama K., Yoshimura A., Steinman L., Christakos S., YoussefS.: 1,25-dihydroxyvitamin D3 ameliorates Th17 autoimmunity viatranscriptional modulation of interleukin-17A. Mol. Cell. Biol., 2011;31: 3653-3669
  Google Scholar
• 24. Kampman M.T., Wilsgaard T., Mellgren S.I.: Outdoor activities anddiet in childhood and adolescence relate to MS risk above the ArcticCircle. J. Neurol., 2007; 254: 471-477
  Google Scholar
• 25. Khattri R., Cox T., Yasayko S.A., Ramsdell F.: An essential role forscurfin in CD4+CD25+ T regulatory cells. Nat. Immunol., 2003; 4: 337-342
  Google Scholar
• 26. Kimball S.M., Ursell M.R., O’Connor P., Vieth R.: Safety of vitaminD3 in adults with multiple sclerosis. Am. J. Clin. Nutr., 2007; 86: 645-651
  Google Scholar
• 27. Kragt J., van Amerongen B., Killestein J., Dijkstra C., Uitdehaag B.,Polman C., Lips P.: Higher levels of 25-hydroxyvitamin D are associatedwith a lower incidence of multiple sclerosis only in women. Mult.Scler., 2009; 15: 9-15
  Google Scholar
• 28. Kurtzke J.F.: Rating neurologic impairment in multiple sclerosis:an expanded disability status scale (EDSS). Neurology, 1983;33: 1444-1452
  Google Scholar
• 29. Lahl K., Loddenkemper C., Drouin C., Freyer J., Arnason J., Eberl G.,Hamann A., Wagner H., Huehn J., Sparwasser T.: Selective depletionof Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med.,2007; 204: 57-63
  Google Scholar
• 30. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T.,Spiegelman D., Ascherio A.: Temporal relationship between elevationof Epstein-Barr virus antibody titers and initial onset of neurologicalsymptoms in multiple sclerosis. JAMA, 2005; 293: 2496-2500
  Google Scholar
• 31. Mahon B.D., Gordon S.A., Cruz J., Cosman F., Cantorna M.T.: Cytokineprofile in patients with multiple sclerosis following vitamin D supplementation.J. Neuroimmunol., 2003, 134: 128-132
  Google Scholar
• 32. Mayne C.G., Spanier J.A., Relland L.M., Williams C.B., Hayes C.E.:1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin Dreceptor to inhibit experimental autoimmune encephalomyelitis. Eur.J. Immunol., 2011; 41: 822-832
  Google Scholar
• 33. Mirzaei F., Michels K.B., Munger K., O’Reilly E., Chitnis T., FormanM.R., Giovannucci E., Rosner B., Ascherio A.: Gestational vitamin D andthe risk of multiple sclerosis in offspring. Ann. Neurol., 2011; 70: 30-40
  Google Scholar
• 34. Mowry E.M., Waubant E., McCulloch C.E., Okuda D.T., EvangelistaA.A., Lincoln R.R., Gourraud P.A., Brenneman D., Owen M.C., Qualley P.,Bucci M., Hauser S.L., Pelletier D.: Vitamin D status predicts new brainmagnetic resonance imaging activity in multiple sclerosis. Ann. Neurol.,2012; 72: 234-240
  Google Scholar
• 35. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A.: Serum25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA,2006; 296: 2832-2838
  Google Scholar
• 36. Munger K.L., Zhang S.M, O’Reilly E., Hernán M.A., Olek M.J., WillettW.C., Ascherio A.:Vitamin D intake and incidence of multiple sclerosis.Neurology, 2004; 62: 60-65
  Google Scholar
• 37. Nashold, F.E., Spach K.M., Spanier J.A., Hayes C.E.: Estrogen controlsvitamin D3-mediated resistance to experimental autoimmuneencephalomyelitis by controlling vitamin D3 metabolism and receptorexpression. J. Immunol., 2009; 183: 3672-3681
  Google Scholar
• 38. Neau J.P., Artaud-Uriot M.S., Lhomme V., Bounaud J.Y., LebrasF., Boissonnot L., Moinot N., Ciron J., Larrieu D., Mathis S.,Godeneche G., Ingrand P.: Vitamin D and multiple sclerosis. A prospectivesurvey of patients of Poitou-Charentes area. Rev. Neurol.,2011; 167: 317-323
  Google Scholar
• 39. Nielsen T.R., Rostgaard K., Nielsen N.M., Koch-Henriksen N., HaahrS., Sørensen P.S., Hjalgrim H.: Multiple sclerosis after infectious mononucleosis.Arch. Neurol., 2007; 64: 72-75
  Google Scholar
• 40. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V.,Sadovnick A.D., Ebers G.C., Canadian Collaborative Study Group: Sexratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol.,2006; 5: 932-936
  Google Scholar
• 41. Orton S.M., Wald L., Confavreux C., Vukusic S., Krohn J.P., RamagopalanS.V., Herrera B.M., Sadovnick A.D., Ebers G.C.: Association of UVradiation with multiple sclerosis prevalence and sex ratio in France.Neurology, 2011; 76: 425-431
  Google Scholar
• 42. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., WangY., Hood L., Zhu Z., Tian Q., Dong C.: A distinct lineage of CD4 T cellsregulates tissue inflammation by producing interleukin 17. Nat. Immunol.,2005; 6: 1133-1141
  Google Scholar
• 43. Pierrot-Deseilligny C., Rivaud-Péchoux S., Clerson P., de Paz R., SouberbielleJ.C.: Relationship between 25-OH-D serum level and relapserate in multiple sclerosis patients before and after vitamin D supplementation.Ther. Adv. Neurol. Disord., 2012; 5: 187-198
  Google Scholar
• 44. Shaygannejad V., Janghorbani M., Ashtari F., Dehghan H.: Effects ofadjunct low-dose vitamin D on relapsing-remitting multiple sclerosisprogression: preliminary findings of a randomized placebo-controlledtrial. Mult. Scler. Int., 2012; 2012: 452541
  Google Scholar
• 45. Shevach E.M.: From vanilla to 28 flavors: multiple varieties of Tregulatory cells. Immunity, 2006; 25: 195-201
  Google Scholar
• 46. Simpson S. Jr., Blizzard L., Otahal P., Van der Mei I., Taylor B.:Latitude is significantly associated with the prevalence of multiplesclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry, 2011;82: 1132-1141
  Google Scholar
• 47. Simpson S. Jr., Taylor B., Blizzard L., Ponsonby A.L., Pittas F., TremlettH., Dwyer T., Gies P., van der Mei I.: Higher 25-hydroxyvitamin D isassociated with lower relapse risk in multiple sclerosis. Ann. Neurol.,2010; 68: 193-203
  Google Scholar
• 48. Smolders J., Damoiseaux J., Menheere P., Hupperts R.: Vitamin Das an immune modulator in multiple sclerosis, a review. J. Neuroimmunol.,2008; 194: 7-17
  Google Scholar
• 49. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R.:Association of vitamin D metabolite levels with relapse rate and disabilityin multiple sclerosis. Mult. Scler., 2008; 14: 1220-1224
  Google Scholar
• 50. Smolders J., Peelen E., Thewissen M., Cohen Tervaert J.W., MenheereP., Hupperts R., Damoiseaux J.: Safety and T cell modulating effectsof high dose vitamin D3 supplementation in multiple sclerosis. PLoSOne, 2010; 5: e15235
  Google Scholar
• 51. Smolders J., Thewissen M., Peelen E., Menheere P., Tervaert J.W.,Damoiseaux J., Hupperts R.: Vitamin D status is positively correlatedwith regulatory T cell function in patients with multiple sclerosis. PLoSOne, 2009; 4: e6635
  Google Scholar
• 52. Soilu-Hänninen M., Airas L., Mononen I., Heikkilä A., Viljanen M.,Hänninen A.: 25-Hydroxyvitamin D levels in serum at the onset of multiplesclerosis. Mult. Scler., 2005; 11: 266-271
  Google Scholar
• 53. Spach K.M., Hayes C.E.: Vitamin D3 confers protection from autoimmuneencephalomyelitis only in female mice. J. Immunol., 2005;175: 4119-4126
  Google Scholar
• 54. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E.: IL-10 signalling is essentialfor 1,25 dihydroxyvitamin D3-mediated inhibition of experimentalautoimmune encephalomyelitis. J. Immunol., 2006; 177: 6030-6037
  Google Scholar
• 55. Spach K.M., Pedersen L.B., Nashold F.E., Kayo T., Yandell B.S., ProllaT.A., Hayes C.E.: Gene expression analysis suggests that 1,25-dihydroxyvitaminD3 reverses experimental autoimmune encephalomyelitisby stimulating inflammatory cell apoptosis. Physiol. Genomics,2004; 18: 141-151
  Google Scholar
• 56. Steinman L., Martin R., Bernard C., Conlon P., Oksenberg J.R.: Multiplesclerosis: deeper understanding of its pathogenesis reveals newtargets for therapy. Annu. Rev. Neurosci., 2002; 25: 491-505
  Google Scholar
• 57. Thacker E.L., Mirzaei F., Ascherio A.: Infectious mononucleosis andrisk for multiple sclerosis: a meta-analysis. Ann. Neurol., 2006; 59: 499-503
  Google Scholar
• 58. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., SimmonsR., Taylor B.V., Butzkueven H., Kilpatrick T.: Past exposure to sun, skinphenotype, and risk of multiple sclerosis: case-control study. Br. Med.J., 2003; 327: 316
  Google Scholar
• 59. Venken K., Hellings N., Hensen K., Rummens J.L., Medaer R.,D’hooghe M.B., Dubois B., Raus J., Stinissen P.: Secondary progressivein contrast to relapsing-remitting multiple sclerosis patients show anormal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J.Neurosci. Res., 2006; 83: 1432-1446
  Google Scholar
• 60. Venken K., Hellings N., Thewissen M., Somers V., Hensen K.,Rummens J.L., Medaer R., Hupperts R., Stinissen P.: CompromisedCD4+CD25high regulatory T-cell function in patients with relapsing-remittingmultiple sclerosis is correlated with a reduced frequency ofFOXP3-positive cells and reduced FOXP3 expression at the single-celllevel. Immunology, 2008; 123: 79-89
  Google Scholar
• 61. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A.: Loss of functionalsuppression by CD4+CD25+ regulatory T cells in patients withmultiple sclerosis. J. Exp. Med., 2004; 199: 971-979
  Google Scholar
• 62. Wan Y.Y., Flavell R.A.: Regulatory T-cell functions are subvertedand converted owing to attenuated Foxp3 expression. Nature, 2007;445: 766-770
  Google Scholar
• 63. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J.,Ebers G.C.; Canadian Collaborative Study Group: Timing of birth andrisk of multiple sclerosis: population based study. BMJ, 2005; 330: 120
  Google Scholar
• 64. Yenamandra S.P., Hellman U., Kempkes B., Darekar S.D., PetermannS., Sculley T., Klein G., Kashuba E.: Epstein-Barr virus encoded EBNA-3binds to vitamin D receptor and blocks activation of its target genes.Cell. Mol. Life Sci., 2010; 67: 4249-4256
  Google Scholar
• 65. Young C.A.: Factors predisposing to the development of multiplesclerosis. QJM, 2011; 104: 383-386
  Google Scholar

Full text